What is Mandrake Bioworks?
Mandrake Bioworks operates as an AI-native biotechnology enterprise, specializing in the development of next-generation gene-editing proteins. By integrating proprietary biological datasets with advanced generative AI models, the company has established a full-stack platform that streamlines the discovery and engineering of molecular tools. Its market position is defined by a dual-focus approach, targeting both agricultural advancements and human therapeutics. This versatility allows the firm to address complex biological challenges with unprecedented precision, positioning it as a key player in the evolving field of synthetic biology and computational protein engineering.
How much funding has Mandrake Bioworks raised?
Mandrake Bioworks has raised a total of $1.7M across 1 funding round:
Angel/Pre-Seed
$1.7M
Angel/Pre-Seed (2026): $1.7M with participation from DeVC, Antler, and Spectrum Impact
Key Investors in Mandrake Bioworks
DeVC
A collective of founders, operators, and investors that provides early-stage capital and operational support to ambitious entrepreneurs building transformative companies.
Antler
A global early-stage venture capital firm that partners with exceptional founders across six continents to launch and scale startups addressing meaningful global challenges.
Spectrum Impact
A family office focused on addressing large-scale societal issues by allocating capital toward ventures that optimize financial, societal, and environmental returns.
What's next for Mandrake Bioworks?
Looking ahead, the strategic deployment of this capital will likely focus on expanding the company's experimental validation pipeline and deepening its intellectual property portfolio. As Mandrake Bioworks transitions from its current development phase toward broader commercial application, the focus will shift to optimizing the efficiency of its gene-editing technologies for clinical and agricultural use cases. The company is expected to prioritize talent acquisition in computational biology and machine learning to maintain its competitive edge. Furthermore, the backing from diverse institutional investors suggests a long-term commitment to scaling the platform's impact, potentially leading to future partnerships with major pharmaceutical and agricultural entities as the technology matures.
See full Mandrake Bioworks company page
